Roche’s breast cancer drug gains more insurance benefits

Korea Biomedical Review

21 May 2019 - The Ministry of Health and Welfare has granted additional reimbursement to Roche’s breast cancer therapy Perjeta (pertuzumab) as a preoperative adjuvant therapy during the early stages of human epidermal growth factor receptor 2 positive breast cancer.

The ministry has also expanded the scope of health insurance coverage from postoperative adjuvant therapy to combination therapies except for Perjeta.

The expanded reimbursement comes after the ministry approving Perjeta as a first-line treatment for patients with HER2-positive metastatic or non-resectable local recurrent breast cancer who have not received anti-HER2 therapy in April last year.

Read Korea Biomedical Review article

Michael Wonder

Posted by:

Michael Wonder